Herminia Rosas, MD
Neurology · Boston, MANPI 1497840177
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,054 of the $14,232 with a category attached, or 98.8%. Neurocrine Biosciences, Inc. accounts for 78.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $11,130 and has fallen 99.8% since, to $20 in 2025.
Across 5 payments — averaging $2846.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$11K
- Novartis$3K
- PTC Therapeutics, Inc.$123
Across 5 payments — averaging $32,696 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$102K
- Neurocrine Biosciences, Inc.$62K
What the payments were for
- Consulting fees$14,05499%
- Food & beverage$1781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 3 | $11,185 |
| Novartis | 1 | $2,924 |
| PTC Therapeutics, Inc. | 1 | $123 |
How this compares
$14,232 in reported general payments places this provider in the 80th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 24 | $126,480 |
| Paroxetine Hcl | 26 | $11,755 |
| Divalproex Sodium | 32 | $1,614 |
| Memantine Hcl | 59 | $1,569 |
| Risperidone | 89 | $1,278 |
| Levetiracetam | 33 | $1,223 |
| Aripiprazole | 75 | $1,197 |
| Galantamine Hbr | 13 | $959 |
| Fluvoxamine Maleate | 13 | $788 |
| Olanzapine | 12 | $653 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 17 | $410 |
| Levothyroxine Sodium | 41 | $374 |
| Duloxetine Hcl | 26 | $275 |
| Bupropion Hcl SrBupropion Hcl | 13 | $233 |
| Trazodone Hcl | 30 | $228 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Christopher WrightBoston$2.5M
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Pushpa NarayanaswamiBoston$420K
- Roy FreemanBoston$390K
- Michael LevyBoston$387K
- Leeann BurtonBoston$325K
- Ilena GeorgeBoston$316K
- Andrew BudsonBoston$304K
- Denis BalabanBoston$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.